Abstract
N6-methyladenosine (m6A) is present in diverse viral RNA and plays important regulatory roles in virus replication and host antiviral innate immunity. However, the role of m6A in regulating JEV replication has not been investigated. Here, we show that the JEV genome contains m6A modification upon infection of mouse neuroblast cells (neuro2a). JEV infection results in a decrease in the expression of m6A writer METTL3 in mouse brain tissue. METTL3 knockdown by siRNA leads to a substantial decrease in JEV replication and the production of progeny viruses at 48 hpi. Mechanically, JEV triggered a considerable increase in the innate immune response of METTL3 knockdown neuro2a cells compared to the control cells. Our study has revealed the distinctive m6A signatures of both the virus and host in neuro2a cells infected with JEV, illustrating the positive role of m6A modification in JEV infection. Our study further enhances understanding of the role of m6A modification in Flaviviridae viruses.
Introduction
Japanese encephalitis virus (JEV) is a major cause of viral encephalitis across Asia, yet the fine-tuned molecular mechanisms it uses to hijack host cells remain partially obscured. This research explores the field of epitranscriptomics, specifically focusing on N6-methyladenosine (m6A) modification. While m6A is known to play critical roles in the replication of other Flaviviridae such as Zika or Dengue, previous findings have been contradictory, showing both pro-viral and anti-viral effects. This study aims to determine whether m6A modification exists on the JEV genome and how the host’s m6A machinery influences the competition between viral replication and the host’s immune system.
Methods
The study employed a multi-pronged approach using both in vitro cell cultures and in vivo mouse models. Researchers used Methylated RNA Immunoprecipitation Sequencing (MeRIP-seq) to map m6A tags on the JEV genome and the host (Neuro2a) transcriptome at 24 and 48 hours post-infection (hpi). Loss-of-function and gain-of-function experiments were conducted using siRNA knockdown and plasmid-based overexpression of "writer" (METTL3/14) and "reader" (YTHDF1/2/3) proteins. Additionally, C57BL/6 mice were infected to observe m6A machinery changes in brain tissue, and Ruxolitinib (a JAK inhibitor) was used to investigate the link between METTL3 and interferon signaling.
Results
The Dynamic JEV Methylome
MeRIP-seq analysis revealed that the JEV genome contains five distinct m6A peaks located in the 5’ UTR/capsid, prM, NS3, and NS5 regions. These sites are dynamic; some peaks appear at 24hpi while others emerge or shift by 48hpi, suggesting the virus's epigenetic signature evolves during its infection cycle.
METTL3 as a Proviral Factor
Unlike some other flaviviruses where m6A acts as an antiviral agent, this study found that m6A is proviral for JEV. Depletion of the writer protein METTL3 led to a substantial decrease in viral RNA and progeny virus titers at 48hpi. Furthermore, in JEV-infected mice, METTL3 expression in brain tissue significantly decreased as the disease progressed, suggesting a potential late-stage breakdown of this machinery.
Immune Evasion Mechanism
The study identified that METTL3 helps JEV replicate by dampening the host's innate immune response. Knocking down METTL3 caused host cells to produce significantly higher levels of Interferon-beta (IFN-β) and Interferon-Stimulated Genes (ISGs). This inhibition of JEV replication was reversed when cells were treated with Ruxolitinib, confirming that METTL3's proviral effect is tied to the suppression of interferon-mediated defenses.
Discussion
This research establishes that m6A modification positively regulates JEV replication by facilitating immune evasion. The discovery of a unique m6A site in the prM region—absent in other closely related flaviviruses—highlights a specific regulatory handle for JEV. While MeRIP-seq provides a high-level map of these modifications, future studies using miCLIP (cross-linking and immunoprecipitation) will be necessary to pinpoint exact nucleotide modifications. Further investigation is also required to determine if m6A tags on viral RNA directly hide the virus from host sensors like RIG-I or if host-modified transcripts are the primary drivers of immune suppression.
Summary updated